IN2014DN10584A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10584A
IN2014DN10584A IN10584DEN2014A IN2014DN10584A IN 2014DN10584 A IN2014DN10584 A IN 2014DN10584A IN 10584DEN2014 A IN10584DEN2014 A IN 10584DEN2014A IN 2014DN10584 A IN2014DN10584 A IN 2014DN10584A
Authority
IN
India
Prior art keywords
defibrotide
biological activity
plasmin
disclosed
activity
Prior art date
Application number
Other languages
English (en)
Inventor
Terenzio Ignoni
Vijay Kumar
Khalid Islam
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46829846&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10584(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gentium Spa filed Critical Gentium Spa
Publication of IN2014DN10584A publication Critical patent/IN2014DN10584A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6435Plasmin (3.4.21.7), i.e. fibrinolysin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21007Plasmin (3.4.21.7), i.e. fibrinolysin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127DNAzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/968Plasmin, i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN10584DEN2014 2012-06-22 2012-06-22 IN2014DN10584A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2012/000193 WO2013190582A1 (en) 2012-06-22 2012-06-22 Euglobulin-based method for determining the biological activity of defibrotide

Publications (1)

Publication Number Publication Date
IN2014DN10584A true IN2014DN10584A (ko) 2015-08-28

Family

ID=46829846

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10584DEN2014 IN2014DN10584A (ko) 2012-06-22 2012-06-22

Country Status (17)

Country Link
US (6) US9902952B2 (ko)
EP (1) EP2864496B2 (ko)
JP (1) JP6198821B2 (ko)
KR (4) KR101948243B1 (ko)
CN (2) CN110079580B (ko)
AU (1) AU2012383169B2 (ko)
BR (1) BR112014031934B1 (ko)
CA (1) CA2874960C (ko)
DK (1) DK2864496T4 (ko)
ES (1) ES2660969T5 (ko)
HK (1) HK1208503A1 (ko)
IL (1) IL236132B (ko)
IN (1) IN2014DN10584A (ko)
MX (1) MX352085B (ko)
RU (1) RU2627177C2 (ko)
SG (1) SG11201408481UA (ko)
WO (1) WO2013190582A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107007617A (zh) 2010-11-12 2017-08-04 真蒂奥姆责任有限公司 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
KR101948243B1 (ko) 2012-06-22 2019-05-21 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (en) * 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
JP7150733B2 (ja) * 2017-01-25 2022-10-11 ケメット エレクトロニクス コーポレーション 自己減衰型mlccアレイ
EP3661484A1 (en) * 2017-08-03 2020-06-10 Jazz Pharmaceuticals Ireland Limited Formulations comprising a nucleic acid in a high concentration
US11571440B2 (en) 2018-04-12 2023-02-07 Jazz Pharmaceuticals Ireland Limited Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
US20230190783A1 (en) 2020-02-28 2023-06-22 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
DE2812943C3 (de) 1978-03-23 1981-05-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung der biologischen Aktivität von Heparin im Plasma
US4853221A (en) 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1170215B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1206341B (it) 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) * 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5231006A (en) 1986-10-16 1993-07-27 Behringwerke Aktiengesellschaft Method for the determination of plasminogen
US4753221A (en) 1986-10-22 1988-06-28 Intravascular Surgical Instruments, Inc. Blood pumping catheter and method of use
JP2907447B2 (ja) 1988-08-24 1999-06-21 中外製薬株式会社 抗血栓剤
IT1231509B (it) 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
JPH0539280A (ja) * 1990-07-20 1993-02-19 Takeda Chem Ind Ltd サツカロアスコルビン酸誘導体および血栓症予防治療剤
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US5624912A (en) 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
US6699985B2 (en) 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
JPH08127539A (ja) 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトil−11を含有する末梢血幹細胞増加剤
EP0801076A4 (en) 1994-11-30 1999-12-15 Chugai Pharmaceutical Co Ltd THROMBOCYTOTIC FACTOR
CA2260014A1 (en) 1996-07-10 1998-01-15 Meiji Milk Products Co., Ltd. Novel use of mk family as hematopoietic factor
CA2259041A1 (en) 1997-04-28 1998-11-05 Arsinur Burcoglu Method of treating hiv infection and related secondary infections thereof
CA2291595A1 (en) 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
GB9719161D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
US6573372B2 (en) 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
CA2377385A1 (en) 1999-06-03 2000-12-14 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
ES2251134T3 (es) 1999-06-08 2006-04-16 Gentium S.P.A. Uso de complejos entre liposomas cationicos y polidesoxirribonucleotidos como medicamentos.
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
EP1147777A1 (en) 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
IL155450A0 (en) 2000-10-20 2003-11-23 Expression Diagnostics Inc Leukocyte expression profiling
AU1788502A (en) 2000-11-28 2002-06-11 Univ Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
CN100347194C (zh) 2000-12-29 2007-11-07 萨文特医药公司 分离的包括含硫酸根部分的表位的分子,抗这样的表位的抗体,和它们的应用
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
US7514414B2 (en) 2001-09-24 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Suppressors of CpG oligonucleotides and methods of use
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1325962A1 (en) * 2001-12-17 2003-07-09 Gentium S.p.A. A method for determining the biological activity of defibrotide
US20050215498A1 (en) 2002-05-31 2005-09-29 Guenther Eissner Method for the protection of endothelial and epithclial cells during chemotherapy
WO2003101468A1 (en) 2002-05-31 2003-12-11 Klinikum Der Universität Regensburg Method for the protection of endothelial and epithelial cells during chemotherapy
EP1534332A4 (en) 2002-07-01 2006-11-22 Savient Pharmaceuticals Inc ANTIBODIES AND ITS USES
JP4483581B2 (ja) 2002-08-06 2010-06-16 東レ株式会社 腎疾患治療又は予防剤及び腎疾患の診断方法
US20050196382A1 (en) 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
WO2005089503A2 (en) 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
CA2623142C (en) * 2004-09-22 2016-01-19 The Regents Of The University Of Colorado, A Body Corporate Methods for a global assay of coagulation and fibrinolysis
CA2598613A1 (en) 2005-03-03 2006-09-14 Gentium S.P.A. Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
US7723127B2 (en) 2005-03-03 2010-05-25 Novx Systems Inc. Immunoassay with extended dynamic range
WO2006119619A1 (en) 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
FR2917172B1 (fr) * 2007-06-07 2014-01-03 Inst Nat Sante Rech Med Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation
CA2692604A1 (en) 2007-07-13 2009-01-22 Elan Pharmaceuticals, Inc. Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
EP2103689A1 (en) 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
US20110191868A1 (en) 2008-04-10 2011-08-04 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
CN102413825A (zh) 2009-04-29 2012-04-11 阿马里纳股份公司 含有epa和心血管剂的药物组合物以及使用其的方法
WO2011057143A1 (en) * 2009-11-06 2011-05-12 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for simultaneous assay of thrombin and plasmin generation
CN107007617A (zh) 2010-11-12 2017-08-04 真蒂奥姆责任有限公司 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
KR101948243B1 (ko) 2012-06-22 2019-05-21 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
EP3661484A1 (en) 2017-08-03 2020-06-10 Jazz Pharmaceuticals Ireland Limited Formulations comprising a nucleic acid in a high concentration

Also Published As

Publication number Publication date
EP2864496A1 (en) 2015-04-29
ES2660969T3 (es) 2018-03-26
US11236328B2 (en) 2022-02-01
JP2015521477A (ja) 2015-07-30
US20150176003A1 (en) 2015-06-25
KR20190112197A (ko) 2019-10-02
ES2660969T5 (es) 2021-09-03
EP2864496B2 (en) 2020-11-25
DK2864496T3 (en) 2018-01-15
KR101948243B1 (ko) 2019-05-21
AU2012383169A1 (en) 2015-01-15
RU2014149089A (ru) 2016-08-10
JP6198821B2 (ja) 2017-09-20
CA2874960C (en) 2021-05-18
MX352085B (es) 2017-11-08
CN104619857A (zh) 2015-05-13
US9902952B2 (en) 2018-02-27
DK2864496T4 (da) 2021-01-04
SG11201408481UA (en) 2015-01-29
KR20180098420A (ko) 2018-09-03
US11085043B2 (en) 2021-08-10
US20210363519A1 (en) 2021-11-25
IL236132A0 (en) 2015-01-29
US20180334672A1 (en) 2018-11-22
WO2013190582A1 (en) 2013-12-27
BR112014031934B1 (pt) 2021-05-04
IL236132B (en) 2018-07-31
RU2627177C2 (ru) 2017-08-03
KR102038357B1 (ko) 2019-10-31
CN110079580B (zh) 2022-12-06
CA2874960A1 (en) 2013-12-27
US20200208148A1 (en) 2020-07-02
US20210388350A1 (en) 2021-12-16
KR20150044877A (ko) 2015-04-27
AU2012383169B2 (en) 2017-12-21
EP2864496B1 (en) 2017-11-29
BR112014031934A2 (pt) 2017-06-27
US11746348B2 (en) 2023-09-05
CN110079580A (zh) 2019-08-02
BR112014031934A8 (pt) 2018-01-02
HK1208503A1 (en) 2016-03-04
MX2014016114A (es) 2015-09-23
US20230357762A1 (en) 2023-11-09
KR20190016148A (ko) 2019-02-15

Similar Documents

Publication Publication Date Title
IN2014DN10584A (ko)
EP3955004A3 (en) Use of fatty acids in methods for detecting cancer
MX348612B (es) Microorganismos y metodos para producir 2,4 - pentadienoato, butadieno, propileno, 1,3 - butanodiol y alcoholes relacionados.
WO2012078806A3 (en) Non-gaming on-line achievement awards
NZ617003A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP2521587A4 (en) RELEASE SYSTEM
UA118658C2 (uk) СПОСІБ ДІАГНОСТИКИ ПРОГНОЗУ ВІДПОВІДІ НА ІНГІБІТОР TNFα
MY197970A (en) Microorganisms and methods for the production of caprolactone
WO2011104517A3 (en) Capacitance detection in electrochemical assay
MX349801B (es) Sustratos de enzimas de ácido nucleico.
MX365302B (es) Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno.
MX344896B (es) Método de operación de la fermentación de un substrato gaseoso que contiene monóxido de carbono.
WO2012177983A3 (en) Microorganisms for producing ethylene glycol and methods related thereto
WO2008114544A1 (ja) 細胞周期可視化プローブ
MY188051A (en) Enzymatic or non-enzymatic biodiesel polishing process
GB201320456D0 (en) Oxidation/reduction measurement
WO2015023631A3 (en) Fatty acid analogs and their use
IN2014CN02937A (ko)
WO2012129263A3 (en) Isothermal amplification of nucleic acid
AR093819A1 (es) Metodo a base de euglobulina para determinar la actividad biologica de defibrotida
ITMI20121259A1 (it) Utilizzo di un substrato in un procedimento per misurare l'attivita' di enzimi proteolitici disponibili.
MY172477A (en) Stemness gene detection and methods thereof
ITMI20121258A1 (it) Utilizzo di un substrato in un procedimento per misurare l'attivita' di enzimi proteolitici.
WO2014064528A3 (ja) α‐ガラクトシダーゼ濃度を測定する方法
UA71210U (ru) СПОСОБ ОПРЕДЕЛЕНИЯ АКТИВНОСТИ γ-ГЛЮТАМИЛТРАНСПЕПТИДАЗЫ В ПАРЕНХИМЕ ПОЧКИ В ЭКСПЕРИМЕНТЕ